Haloperidol Syri (Haloperidol)

Haloperidol Syri is prescribed for several psychiatric indications where dopamine blockade is therapeutic, and it may be used as part of a broader treatment plan.

• Management of schizophrenia, including acute exacerbations.
• Treatment of acute psychotic episodes unrelated to schizophrenia.
• Control of manic episodes in bipolar disorder.
• Reduction of severe agitation or aggression in hospitalized patients.
• Adjunctive therapy for Tourette syndrome when other options are insufficient.
• Prevention of relapse in patients stabilized on haloperidol therapy.
• Use in combination with other antipsychotics when monotherapy is inadequate.

Haloperidol Syri can produce a range of adverse effects, which are generally categorized by frequency and severity; patients should be monitored regularly for both common and potentially serious reactions.

Common

• Extrapyramidal symptoms such as tremor, rigidity, and akathisia.
• Drowsiness or sedation.
• Dry mouth and constipation.
• Weight gain or increased appetite.
• Blurred vision or ocular disturbances.
• Nausea or vomiting.
• Orthostatic hypotension.
• Insomnia or sleep disturbances.
• Sexual dysfunction, such as decreased libido.

Serious

• Neuroleptic malignant syndrome, a life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary movements.
• Significant cardiac arrhythmias, including QT prolongation.
• Severe depression or suicidal thoughts.
• Hepatic dysfunction with elevated enzymes.
• Seizures in predisposed individuals.
• Elevated prolactin levels leading to galactorrhea.

When prescribing Haloperidol Syri, clinicians consider several precautionary factors to minimize risk and ensure appropriate use.

• Assess patient history for cardiovascular disease, especially arrhythmias or prolonged QT interval.
• Evaluate for movement disorders or prior extrapyramidal reactions before initiating therapy.
• Use caution in patients with hepatic or renal impairment; dose adjustments may be required.
• Monitor for signs of neuroleptic malignant syndrome during the first weeks of treatment.
• Consider pregnancy and lactation status; the safety profile in these populations is not well established.
• Review concomitant medications that may increase the risk of sedation or cardiac effects.

Haloperidol Syri may interact with other medicines, altering its effectiveness or increasing adverse effects; awareness of key interactions guides safe prescribing.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels.
• Other antipsychotics or dopamine antagonists that may exacerbate extrapyramidal symptoms.
• Medications known to prolong the QT interval, such as certain antiarrhythmics or fluoroquinolones.

Use with caution

• CNS depressants (e.g., benzodiazepines, opioids) that can increase sedation.
• Anticholinergic agents, which may mask early signs of extrapyramidal side effects.
• CYP2D6 substrates (e.g., metoprolol, codeine) where haloperidol may affect their metabolism.